Vical Expands Infectious Disease Portfolio With Novel

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas
  • Development and potential commercial synergies with existing CMV program
  • Targeting Phase 1 initiation in first half of 2016
  • 2015 cash burn guidance remains unchanged

SAN DIEGO, March 25, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL ) today announced that it has expanded its infectious disease portfolio with the addition of a novel antifungal, ASP2397, in-licensed from Astellas Pharma Inc. (TOKYO:4503) ("Astellas"). ASP2397 represents a potential new class of antifungal compounds to address invasive Aspergillus infections, which are major causes of morbidity and mortality in immunocompromised patients, including transplant recipients. ASP2397 is differentiated by a new mechanism of action and has a low propensity for P450 drug-drug interactions. In preclinical studies to date, it has demonstrated faster fungicidal activity than marketed drugs and activity against azole-resistant fungal pathogens. As part of the agreement, Astellas, which is also Vical's partner for the ASP0113 CMV vaccine program in transplant recipients, will become a shareholder in Vical.

"It is exciting to see a novel antifungal with preclinical data showing potent and rapid fungicidal activity, and low potential for drug-drug interactions. Such a drug could become a treatment of choice for front-line therapy of invasive fungal infections," said John R. Perfect, M.D., Chief of Division of Infectious Diseases at Duke University Medical Center.

Under the terms and conditions of the license agreement, Astellas granted Vical an exclusive worldwide license to develop and commercialize ASP2397. Astellas will receive Vical common stock equivalent to approximately 1% of outstanding shares and $250 thousand in cash. Astellas will also be eligible for up to $100 million in aggregate milestone payments, the vast majority of which are commercial and sales milestones, and single-digit royalties on net sales. The above agreement does not impact Vical's cash burn guidance, which remains at between $12 million and $15 million for 2015.

"ASP2397 is an exciting opportunity that has arisen out of the relationship we have built with Astellas," said Vijay B. Samant, Vical's President and CEO. "While advancing our CMV and HSV-2 programs remains the top priority at Vical, this novel candidate adds depth to our pipeline and strengthens Vical's position as an infectious disease company."

"ASP2397 is a unique antifungal discovered at Astellas, and we are pleased to partner it with Vical, who we believe has the right capabilities to develop this compound and bring it to market," said Naoki Okamura, Corporate Vice President and Global Head of Business Development at Astellas.

ASP2397 is a novel natural product discovered by Astellas from leaf litter fungus collected in a Malaysian national park. In vitro and in vivo data were featured in two posters presented during the ICAAC 2014 meeting last September. Most of the IND-enabling preclinical studies have been completed by Astellas, and Vical is targeting initiation of a Phase 1 trial in the first half of 2016.

Vical consulted an expert team of advisors during the evaluation of ASP2397 and is forming a Clinical Advisory Board (CAB) to help direct the development program. Initial members of the CAB include:

  • John R. Perfect, M.D., Chief of Division of Infectious Diseases, Duke University Medical Center
  • Dennis Schmatz, Ph.D., consultant, 30-year veteran of Merck and team leader for Cancidas (caspofungin)
  • Michael R. Hodges, M.D., consultant, 17-year veteran of Pfizer and team leader for Vfend (voriconazole)

Vical intends to develop ASP2397 as a front-line therapy for invasive aspergillosis and as part of combination regimen for preemptive treatment of fungal infections, which may represent a meaningful commercial opportunity within the $4 billion global market for systemic antifungals. Current treatment options have limited efficacy, as approximately 50-60% of allogeneic hematopoietic stem cell transplant recipients with invasive aspergillosis infections die within 12 weeks. Over the past 30 years, only one new class of antifungal drugs (echinocandins) has been introduced.

Conference Call

Vical will conduct a conference call and webcast tomorrow, March 26, at 8:30 a.m. Eastern Time. Listeners may access the accompanying slide presentation through the webcast at www.vical.com . The call and webcast will be open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2308 (preferred), or (888) 312-3048 (toll-free), and reference confirmation code 2695093. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 2695093. The webcast portion of the call will be available live and archived through the events page at www.vical.com . For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at ir@vical.com .

About Vical

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com .

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include cash burn guidance, the potential benefits of ASP2397, Vical's capabilities to develop ASP2397, Vical's development plans and timelines for ASP2397, the potential market opportunity for ASP2397, and potential payments under the license agreement with Astellas. Risks and uncertainties include whether Vical or others will continue development of ASP2397, whether planned clinical development of ASP2397 will begin when expected, or at all, whether the results of future preclinical or clinical studies will be consistent with prior preclinical studies or will otherwise merit further development; whether Vical will achieve levels of revenues and control expenses to meet its financial projections; whether Vical or its collaborative partners will seek or gain approval to market any product candidates, including ASP2397; whether pending legislation related to the development or drug candidates such as ASP2397 will be enacted in its current form or at all, and the ultimate impact of any such legislation; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Andrew Hopkins (858) 646-1127 Website: www.vical.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 83

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 84

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Funding Opportunity for Cartier Silver Corporation

Updated Category News Views 136

Cartier Silver Corporation Announces Financing Initiative Cartier Silver Corporation (CSE: CFE) has exciting news that emphasizes its commitment to growth and exploration. The Company is moving forward with a non-brokered private placement, intending to raise up to $1.5 million. Details of the Private Placement Under the terms of this Private Placement, Cartier Silver...

Continue Reading
Dynex Capital, Inc. Announces Exciting Dividend Updates

Updated Category News Views 56

Dynex Capital, Inc. Dividend Updates Dynex Capital, Inc. has recently made some important announcements regarding its dividends. The Board of Directors declared a cash dividend of $0.13 per share on its Common Stock (NYSE: DX) for September. Additionally, they revealed a quarterly cash dividend of $0.43125 per share for the 6.900% Series C Fixed-to-Floating Rate...

Continue Reading
Innovative Detox Solution to Alleviate Pain and Stress

Updated Category News Views 163

Introducing an Innovative Detox Solution In a world where wellness and self-care are becoming increasingly essential, an inventive product named TREETOX has emerged, aiming to redefine the way we think about detoxification and pain relief. Invented by a visionary in Pittsburgh, this product presents a seamless alternative for individuals battling ADHD and autism who are...

Continue Reading
WesBanco, Inc. Appoints Amby Bauer as Market President

Updated Category News Views 174

WesBanco, Inc. Names Amby Bauer as Western Pennsylvania Market President WesBanco, Inc. (NASDAQ: WSBC), a prominent multi-state banking institution, has announced the appointment of Amby Bauer as the new Western Pennsylvania Market President and Senior Commercial Banker. This strategic move comes at a time when the bank is focusing on enhancing its service provisions in...

Continue Reading
Svitzer Group Reports Major Shareholder Update from Morgan Stanley

Updated Category News Views 268

Svitzer Group Announces Major Shareholder Update In a significant development, Svitzer Group A/S has received a noteworthy notification concerning major shareholder dealings. The global leader in towage and marine services, Svitzer Group, confirmed a recent communication from Morgan Stanley regarding their shareholdings. As of a specified date, Morgan Stanley reportedly...

Continue Reading